Serina Therapeutics (Serina Therapeutics) Cash-to-Debt : 1.07 (As of Jun. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Serina Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2023 was 1.07.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Serina Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Serina Therapeutics's Cash-to-Debt or its related term are showing as below:

SER' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29 Med: 1.07 Max: 3.29
Current: 1.07

During the past 2 years, Serina Therapeutics's highest Cash to Debt Ratio was 3.29. The lowest was 0.29. And the median was 1.07.

SER's Cash-to-Debt is ranked worse than
75.71% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs SER: 1.07

Serina Therapeutics Cash-to-Debt Historical Data

The historical data trend for Serina Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Serina Therapeutics Cash-to-Debt Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

Cash-to-Debt

3.29

0.29

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Cash-to-Debt	3.29	N/A	0.29	1.07

Competitive Comparison of Serina Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Serina Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Serina Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Cash-to-Debt falls into.

Serina Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Serina Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.532	/	(0.128	+	1.68)
	=	0.29

Serina Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.722	/	(7.805	+	0.388)
	=	1.06

Serina Therapeutics (AMEX:SER) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Serina Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024